BioSpace News Archive

In line with Asymchem’s continuous strategic layout and development, the organization has welcomed Dr. Cheng Yi Chen as a senior executive.

seqWell, a global provider of genomic library and multiplexing workflow solutions, announced the launch of their new portfolio of Tagify loaded-transposase reagents, including Tagify i5 UMI adapter-loaded Tn5.

The Lupus Foundation of America, the national force devoted to solving the cruel mystery of lupus, announced the appointment of Louise Vetter as president and chief executive officer, effective July 17, 2024.

COUR Pharmaceuticals announced the appointment of Tim Walbert, an industry veteran with more than 30 years of leadership experience in biotech, to its Board of Directors, effective immediately.

Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is thrilled to announce the publication of the research supporting the development of the ClarityDX Prostate test.

Repare Therapeutics Inc. today reported positive initial data from the ongoing Phase 1 MINOTAUR clinical trial evaluating lunresertib (RP-6306) in combination with FOLFIRI in patients with advanced solid tumors.

Today, the U.S. Food and Drug Administration issued a draft guidance, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” to assist medical product sponsors in submitting Diversity Action Plans to support certain clinical studies.

Masimo Corporation filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on July 25, 2024.

In a landmark study, researchers from Children’s Hospital of Philadelphia found that two separate objective assessment tools and nonverbal measurements of IQ can help assess cognitive function in children with Aicardi Goutières Syndrome, allowing treatment teams to provide appropriate support and interventions.

Nearly one out of four Americans (23.3%) suffer from chronic low back pain. A new study finds that low-intensity continuous ultrasound, such as ZetrOZ Systems’ sustained acoustic medicine (sam®) technology, alleviates the symptoms of chronic lower back pain and reduces the need for pain medication.